SC
FPRX

Sophrosyne Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Sophrosyne Capital’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-22,300
Closed -$438K – 85
2014
Q1 		$438K Buy
+22,300
New +$379K 0.38% 48

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sophrosyne Capital's FPRX Position: Q2 2014 in Review

Sophrosyne Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2014, closing a stake of 22,300 shares — an estimated $438K sold.

Sophrosyne Capital first reported a position in FPRX in Q1 2014 and held it in 1 quarter. The position peaked at $438K in Q1 2014. 62 funds tracked by Wall St. Rank hold FPRX as of Q2 2014.

  • Sophrosyne Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 22,300 Five Prime Therapeutics, Inc. shares in Q2 2014, an estimated $438K.
  • Sophrosyne Capital first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • Sophrosyne Capital's Five Prime Therapeutics, Inc. position peaked at $438K in Q1 2014.
  • 62 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2014.

Based on Sophrosyne Capital's 13F filing for Q2 2014, filed 14 Aug 2014.